TrialAnnals of oncology : official journal of the European Society for Medical Oncology2013

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

M Weiner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.